Syncona
British investment trust
From Wikipedia, the free encyclopedia
Syncona (LSE: SYNC) is a large British closed-ended investment trust dedicated to life science investments. Co-founded as Syncona Partners in 2012 by former CEO Martin Murphy and the Wellcome Trust,[1] before merging with the Battle Against Cancer Investment Trust ('BACIT') in December 2016 and listing publicly,[2] the company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.[3] Its Chair is Melanie Gee.[4]
